• Amgen research executive Pradeep Natarajan sees an opportunity to connect human genetics with drug development, he said in an interview.
• He cited Repatha as an example of genetic findings guiding medicine development, with PCSK9 variants helping identify the drug target.
• Natarajan highlighted deCODE Genetics' population research capabilities as complementary to the company's drug development expertise.
• Genetic discoveries require further biological validation and continued testing before they can translate into potential medicines, he said.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.